Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers

NCT04403685 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

129

Enrollment

OTHER

Sponsor class

Stopped Safety

Conditions

COVID
SARS Pneumonia
Cytokine Release Syndrome

Interventions

DRUG: Tocilizumab

Sponsor

Beneficência Portuguesa de São Paulo

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]